share_log

HUTCHMED Announces That The New Drug Application For TAZVERIK (Tazemetostat) Has Been Granted Conditional Approval In China For The Treatment Of Adult Patients With Relapsed Or Refractory Follicular Lymphoma With EZH2 Mutation Who Have Received At...

Benzinga ·  Mar 21 05:03

HUTCHMED Announces That The New Drug Application For TAZVERIK (Tazemetostat) Has Been Granted Conditional Approval In China For The Treatment Of Adult Patients With Relapsed Or Refractory Follicular Lymphoma With EZH2 Mutation Who Have Received At Least Two Prior Systemic Therapies

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment